Black Diamond Therapeutics' Silevertinib Shows 15.2-Month Median PFS And 60% Response Rate With CNS Activity In EGFR Non-Classical Mutation NSCLC Phase 2 Study

• Preliminary mPFS of 15.2 months; mDOR not reached
• Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases
• ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC
• Dose dependent and manageable AE profile, no new safety signals observed
• Webcast on Thursday, May 21, 2026 at 5:30 pm EDT
  
  
  
   

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director, Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, at the 2026 American Society of Clinical Oncology® (ASCO®) Annual Meeting on Saturday, May 30, 2026, 1:15 PM-2:45 PM CDT.